Tirzepatide is a dual GLP-1 and GIP receptor agonist. It acts on two gut-hormone pathways involved in appetite and metabolism. Your dose is set and adjusted by a licensed provider, only if treatment is appropriate.
Dual GLP-1 and GIP receptor agonism: two incretin pathways.
Published evidence
In SURMOUNT-1, higher-dose tirzepatide produced substantial mean weight loss over 72 weeks in trial adults with obesity. Individual results vary.
How it’s used here
Once weekly, titrated by your provider. Compounded after a valid prescription.
Prescribed, not sold
A licensed provider authorizes treatment only if it is medically appropriate, never as a cart-only purchase.
Dual pathway
Targets GLP-1 and GIP receptors. That dual mechanism is why SURMOUNT studied it as a dual agonist, not a guarantee of any one person’s outcome.
Supported after
Dose adjustments and provider messaging are included so the plan can change with your response.
What to expect
1
Early weeks
Getting started
You typically begin at a low dose so your body can adjust. Appetite changes are common but not universal. GI side effects may appear during titration and often improve with time or dose changes.
2
Titration period
Stepping the dose
Your provider may increase the dose on a schedule that fits you. Progress, when it occurs, is gradual. Starting weight, adherence, and lifestyle matter. Individual results vary.
3
Maintenance
Finding your dose
You may settle into a maintenance dose. SURMOUNT trial averages describe research populations at specific brand doses, not a guarantee for compounded therapy or for any one person.
4
Ongoing
Reviewed and adjusted
Your provider can review response and refine the plan. This is ongoing clinical care, not a one-time ship-and-forget order.
Every tirzepatide prescription is written by a US-licensed provider who has reviewed your history, and who can decline when treatment is not appropriate.
The DirectGLP standard
Compounded medications contain clinically studied active ingredients but are prepared for you by a state-licensed 503A pharmacy. They are not the same as FDA-approved brand products (for example Zepbound® or Mounjaro®) and are not FDA-approved finished drugs. Trial results apply to the studied brand regimens and populations.
Asked plainly
Semaglutide targets the GLP-1 receptor. Tirzepatide targets both GLP-1 and GIP receptors. That dual mechanism is why it was studied as a dual agonist. Which option fits you is a clinical decision based on your history, goals, and tolerance, not a universal “better.”
Brand-name tirzepatide products are FDA-approved for specific indications. The medication DirectGLP dispenses is compounded by a state-licensed 503A pharmacy and is not an FDA-approved finished product.
In SURMOUNT-1, adults on tirzepatide had substantial mean weight loss over 72 weeks, with higher doses associated with greater average loss in that trial. Those averages are not a personal guarantee. Compounded products were not the study drug. Your provider can discuss what is realistic for you.
Because it is a prescription medication. A licensed provider must review your history and decide it is appropriate before it can be dispensed. The assessment and provider review carry no charge unless you proceed after a prescription.
Before you begin
Not for everyone.
GLP-1 therapy isn't appropriate for every patient. A licensed provider screens for these during your assessment, so please share your full history.
Personal/family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy, planning pregnancy, or breastfeeding
History of pancreatitis or known allergy to the medication
GLP-1 receptor agonists carry a boxed warning regarding thyroid C-cell tumors observed in rodents; it is unknown whether they cause medullary thyroid carcinoma (MTC) in humans. They are contraindicated in patients with a personal or family history of MTC or MEN 2. These medications are compounded by state-licensed 503A pharmacies and are not FDA-approved finished products. This page is educational and is not medical advice. Eligibility is always determined by a licensed provider after reviewing your full history.
Prescription required
